Serum concentration of taurochenodeoxycholic acid predicts clinically significant portal hypertension

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F23%3A00083840" target="_blank" >RIV/00023001:_____/23:00083840 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/23:10451893 RIV/00064165:_____/23:10451893

Výsledek na webu

<a href="https://www.webofscience.com/wos/woscc/full-record/WOS:000890252700001" target="_blank" >https://www.webofscience.com/wos/woscc/full-record/WOS:000890252700001</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/liv.15481" target="_blank" >10.1111/liv.15481</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Serum concentration of taurochenodeoxycholic acid predicts clinically significant portal hypertension

Popis výsledku v původním jazyce

Background &amp; AimsSeverity of portal hypertension is usually quantified by measuring the hepatic venous pressure gradient (HVPG). However, due to its invasiveness, alternative markers are being sought. Bile acids (BA), being synthesized, metabolized, and transported by the liver, seem to have the potential to serve as endogenous markers. The aim of the present study was to determine whether serum BA reflect the severity of portal hypertension. MethodsWe correlated serum concentrations of individual BA with portal pressure (as HVPG) in an exploratory cohort of 21 cirrhotic patients with portal hypertension. The predictive potential of selected candidates was then confirmed in an independent validation cohort (n = 214). Additionally, nine previously published noninvasive markers were added to the stepwise logistic regression model to identify the most relevant ones, which were eventually used to create a prognostic index of portal hypertension. ResultsSerum levels of taurochenodeoxycholic acid (TCDCA) significantly correlated with HVPG and showed a high potential to predict clinically significant portal hypertension (HVPG &gt;= 10 mm Hg: AUROC = 0.97 +/- 0.06). This was confirmed in the validation cohort (AUROC = 0.96 +/- 0.01). The predictive index (constructed based on AST/ALT, spleen diameter, and TCDCA concentration) was able to distinguish clinically significant portal hypertension with 95% sensitivity and 76% specificity. ConclusionsTCDCA seems to be a promising noninvasive marker of clinically significant portal hypertension. Its predictive potential may be further enhanced when it is combined with both the AST/ALT ratio and spleen diameter.

Název v anglickém jazyce

Serum concentration of taurochenodeoxycholic acid predicts clinically significant portal hypertension

Popis výsledku anglicky

Background &amp; AimsSeverity of portal hypertension is usually quantified by measuring the hepatic venous pressure gradient (HVPG). However, due to its invasiveness, alternative markers are being sought. Bile acids (BA), being synthesized, metabolized, and transported by the liver, seem to have the potential to serve as endogenous markers. The aim of the present study was to determine whether serum BA reflect the severity of portal hypertension. MethodsWe correlated serum concentrations of individual BA with portal pressure (as HVPG) in an exploratory cohort of 21 cirrhotic patients with portal hypertension. The predictive potential of selected candidates was then confirmed in an independent validation cohort (n = 214). Additionally, nine previously published noninvasive markers were added to the stepwise logistic regression model to identify the most relevant ones, which were eventually used to create a prognostic index of portal hypertension. ResultsSerum levels of taurochenodeoxycholic acid (TCDCA) significantly correlated with HVPG and showed a high potential to predict clinically significant portal hypertension (HVPG &gt;= 10 mm Hg: AUROC = 0.97 +/- 0.06). This was confirmed in the validation cohort (AUROC = 0.96 +/- 0.01). The predictive index (constructed based on AST/ALT, spleen diameter, and TCDCA concentration) was able to distinguish clinically significant portal hypertension with 95% sensitivity and 76% specificity. ConclusionsTCDCA seems to be a promising noninvasive marker of clinically significant portal hypertension. Its predictive potential may be further enhanced when it is combined with both the AST/ALT ratio and spleen diameter.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Liver international

ISSN

1478-3223

e-ISSN

1478-3231

Svazek periodika

43

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

8

Strana od-do

888-895

Kód UT WoS článku

000890252700001

EID výsledku v databázi Scopus

2-s2.0-85142733634